Guardian Pharmacy Services Reiterates Its Previously Announced 2025 Revenue Guidance Of $1.43B To $1.45B; For 2026, Co. Expects Revenue In The Range Of $1.40B To $1.42B

Guardian Pharmacy Services (NYSE:GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes.

The Company will review these and other business updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026, at 4:30 p.m. PT (7:30 p.m. ET).

CEO Commentary:

"Over the past year, we've focused on strengthening our business and preparing for changes in the operating environment, especially as it relates to the Inflation Reduction Act price reductions that will come into effect in 2026," said Fred Burke, President and Chief Executive Officer of Guardian Pharmacy Services.

"Based on the actions we've taken and the visibility we have today, we expect to continue our low double-digit adjusted EBITDA growth trajectory in 2026. Importantly, we are able to do this without changing how we care for residents or support our facility partners."

Financial Outlook Update

Guardian is reiterating its previously announced 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million. The Company is also announcing its initial outlook for 2026.

For 2026, Guardian expects revenue in the range of $1.40 billion to $1.42 billion, after the effects of the drug-pricing reforms under the Inflation Reduction Act and the more recently announced wholesale acquisition cost ("WAC") reductions. Excluding the impact of the mandatory drug price reductions, the Company would have projected 2026 revenue growth in the high single digits.

The Company expects 2026 adjusted EBITDA in the range of $115 million to $118 million, representing approximately 11% year-over-year growth from 2025 guidance and consistent with Guardian's historical projected low double-digit adjusted EBITDA growth rate. This 2026 outlook reflects a structural improvement in adjusted EBITDA margin to above 8%, a step-up from 2025.